These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 17175328

  • 1. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
    Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J.
    Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
    [Abstract] [Full Text] [Related]

  • 2. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E, Esrailian E, Spiegel BM.
    Aliment Pharmacol Ther; 2007 Oct 15; 26(8):1147-61. PubMed ID: 17894657
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.
    Am J Gastroenterol; 2013 Sep 15; 108(9):1458-63. PubMed ID: 23877348
    [Abstract] [Full Text] [Related]

  • 4. Rifaximin for the treatment of hepatic encephalopathy.
    Mantry PS, Munsaf S.
    Transplant Proc; 2010 Dec 15; 42(10):4543-7. PubMed ID: 21168733
    [Abstract] [Full Text] [Related]

  • 5. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.
    Leevy CB, Phillips JA.
    Dig Dis Sci; 2007 Mar 15; 52(3):737-41. PubMed ID: 17245628
    [Abstract] [Full Text] [Related]

  • 6. Pharmacoeconomics of hepatic encephalopathy.
    Neff G.
    Pharmacotherapy; 2010 May 15; 30(5 Pt 2):28S-32S. PubMed ID: 20412038
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R, Trifan A.
    Rev Med Chir Soc Med Nat Iasi; 2012 May 15; 116(4):1021-7. PubMed ID: 23700882
    [Abstract] [Full Text] [Related]

  • 8. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N.
    J Clin Gastroenterol; 2012 Feb 15; 46(2):168-71. PubMed ID: 22011586
    [Abstract] [Full Text] [Related]

  • 9. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
    Butt NI, Butt UI, Kakar AATK, Malik T, Siddiqui AM.
    J Coll Physicians Surg Pak; 2018 Feb 15; 28(2):115-117. PubMed ID: 29394969
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K, Sonawale A.
    J Assoc Physicians India; 2017 Aug 15; 65(8):42-46. PubMed ID: 28799305
    [Abstract] [Full Text] [Related]

  • 11. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P, Sharma BC, Sarin SK.
    Eur J Gastroenterol Hepatol; 2010 May 15; 22(5):526-31. PubMed ID: 20009938
    [Abstract] [Full Text] [Related]

  • 12. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
    Volk ML, Burne R, Guérin A, Shi S, Joseph GJ, Heimanson Z, Ahmad M.
    J Med Econ; 2021 May 15; 24(1):202-211. PubMed ID: 33464935
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of rifaximin in combination with lactulose in end-stage liver disease patients with MELD greater than 20: a single center experience.
    Mantry PS, Mehta A, Graydon R.
    Transplant Proc; 2014 Dec 15; 46(10):3481-6. PubMed ID: 25498076
    [Abstract] [Full Text] [Related]

  • 14. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
    Abdo-Francis JM, Pérez-Hernández JL, Hinojosa-Ruiz A, Hernández-Vásquez JR.
    Rev Gastroenterol Mex; 2010 Dec 15; 75(2):135-41. PubMed ID: 20615780
    [Abstract] [Full Text] [Related]

  • 15. Rifaximin treatment in hepatic encephalopathy.
    Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP.
    N Engl J Med; 2010 Mar 25; 362(12):1071-81. PubMed ID: 20335583
    [Abstract] [Full Text] [Related]

  • 16. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR, Sigal SH.
    Hosp Pract (1995); 2013 Aug 25; 41(3):48-59. PubMed ID: 23948621
    [Abstract] [Full Text] [Related]

  • 17. Management of hepatic encephalopathy in the hospital.
    Leise MD, Poterucha JJ, Kamath PS, Kim WR.
    Mayo Clin Proc; 2014 Feb 25; 89(2):241-53. PubMed ID: 24411831
    [Abstract] [Full Text] [Related]

  • 18. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C, Schütte K, Kropf S, Schmitt FC, Vasapolli R, Kliegis LM, Riegger A, Malfertheiner P.
    Trials; 2016 Feb 29; 17(1):111. PubMed ID: 26926775
    [Abstract] [Full Text] [Related]

  • 19. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
    Rahimi RS, Brown KA, Flamm SL, Brown RS.
    Am J Med; 2021 Nov 29; 134(11):1330-1338. PubMed ID: 34242619
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.